Baird Capital announced today that it has invested in Oncology Analytics, a leading data analytics and technology-enabled services company dedicated to helping health plans, providers, and patients with solutions that are purpose-built for oncology.
“The increasing cost of cancer care in the US has created an enormous burden for health plans and patients, which requires new thinking and a radical approach to solve,” said Mike Liang, Partner at Baird Capital. “Oncology Analytics’ strategy, which puts data-science and real-world evidence at the center of the treatment decision-making process, demonstrates the type of innovative leadership needed in healthcare. Baird Capital looks forward to supporting Oncology Analytics to accelerate its mission.”
The $28 million, Series C financing led by Baird Capital will enable Oncology Analytics to expand its oncology-focused capabilities, accelerate real-world data and analytics solutions for health plans, and increase the market share of its technology-enabled utilization management solution.
For more information, please read Oncology Analytics’ news release.